---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-24-000032"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T11:05:31.810042+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acumen appoints Dr. James Doherty as President and Chief Development Officer

## Summary
- Dr. James Doherty appointed President and Chief Development Officer effective Feb 1, 2024, reporting to CEO Daniel O'Connell.
- Doherty previously served as Chief Development Officer at Sage Therapeutics, contributing to two FDA approvals for postpartum depression.
- He will oversee clinical/non-clinical development, CMC, and regulatory functions as Acumen prepares to initiate ALTITUDE-AD study for ACU193.
- Daniel O'Connell's title changes to CEO (previously CEO and President) as Doherty assumes the President role.
- Doherty led Alzheimer's research at AstraZeneca and holds a Ph.D. in Neurobiology from Georgetown University.

## SEC filing metadata
- accession: 0001576885-24-000032
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000032/0001576885-24-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000032/abos-20240201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-24-000032
- JSON: https://secwatch.observer/filing/0001576885-24-000032.json
- Plain text: https://secwatch.observer/filing/0001576885-24-000032.txt

## Key facts
- Executive change
  James Doherty was appointed as President and Chief Development Officer at Acumen Pharmaceuticals, Inc..
  - Action: appointed
  - Role: President and Chief Development Officer
  source text: James Doherty has been appointed as its President and Chief Development Officer, effective February 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000032/0001576885-24-000032-index.htm
- Executive change
  Daniel O'Connell changed role as Chief Executive Officer at Acumen Pharmaceuticals, Inc..
  - Action: updated
  - Role: Chief Executive Officer
  source text: Effective upon the commencement of Mr. Doherty's employment, Daniel O'Connell's position would be updated to Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000032/0001576885-24-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.